medi-3617
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01248949)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Angiopoietin-2INHIBITOR
ANGPT2 inhibitor
VPS51 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109298 ↗
Also known as
- medi3617
- medi-3617
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02141542 | Phase 1 | May 1, 2014 | Harvard University, MedImmune |
| NCT01248949 | Phase 1 | Oct 1, 2010 | MedImmune |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 2 | 1 | 1 | 2010 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1